Lapse of unlisted options
Released
Released
Announcement PDF
ASX Announcement
1 September 2020
Lapse of Unlisted Share Options
Invion Limited (ASX.IVX) wishes to advise that on 31 August 2020 18,171,743 unlisted share options
with an exercise price of $0.03 per option and an expiry date of 12 February 2023 lapsed,
unexercised, following the retirement of Melanie Farris as director.
Investor enquiries
Managing Director & CEO, Craig Newton
T: +61 3 9081 6005
E: investor@inviongroup.com
Media enquires
Brendon Lau
T: 0409 341 613
E: brendon@vantagepointpartners.com.au
About Invion
Invion is a life-science company that is leading the global research and development of PhotosoftTM
technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand
license rights to the PhotosoftTM technology. Research and clinical trials are funded by the
technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company.
Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee
of the Board of Invion Limited. For further information please contact investor@inviongroup.com.
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy.
PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce
cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune
system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which
are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins,
and invasion and infiltration of a tumour by leukocytes.
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia
P: +61 9692 7222 W: www.inviongroup.com
Share your feedback
Discover